TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: Case report

Clin Res Hepatol Gastroenterol. 2023 Aug;47(7):102169. doi: 10.1016/j.clinre.2023.102169. Epub 2023 Jun 21.

Authors

Bin Guo¹, Yi Zhou¹, Zhicheng Liu¹, Qian Chen¹, Xiaoping Chen¹, Zhenyu Xiao²

Affiliations

¹ Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
² Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address: xiaozhenyu58@163.com.

PMID: 37352923
DOI: 10.1016/j.clinre.2023.102169

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Carcinoma, Hepatocellular* / therapy
Chemoembolization, Therapeutic*
Humans
Liver Neoplasms* / therapy
Programmed Cell Death 1 Receptor
Treatment Outcome

Substances

Programmed Cell Death 1 Receptor